HRMY - Harmony Biosciences Holdings, Inc.

QQQ $ 474.86 $ 2.12 (0.45 %)

DIA $ 414.87 $ 2.97 (0.72 %)

SPY $ 561.82 $ 2.92 (0.52 %)

TLT $ 100.40 $ 0.27 (0.27 %)

GLD $ 238.66 $ 2.35 (0.99 %)

Previous Close

$ 38.91

Open

Bid

$ 38.90 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 18.61 - $ 39.21

Volume

339,907

Average Volume

Market Cap

2.21B

Beta (5Y Monthly)

$ 0.75

PE Ratio (TTM)

$ 19.18

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	04-30-2024	03-31-2024	10-Q
3	02-22-2024	12-31-2023	10-K
4	10-31-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	02-21-2023	12-31-2022	10-K
8	11-01-2022	09-30-2022	10-Q
9	08-02-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-10-2021	06-30-2021	10-Q
14	05-11-2021	03-31-2021	10-Q
15	03-25-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Harmony Bioscien...
09/12/2024 10:37:52

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

neurology-focused-harmony-biosciences-gains-confidence-with-wakix-sales-surge-strategic-pipeline-expansion-bullish-analyst-says

Neurology-Focused Harmony Biosciences Gain...
09/10/2024 18:56:30

UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's pot...

Unveiling 6 Analyst Insights On Harmony Bi...
09/10/2024 14:01:22

UBS Initiates Coverage On Harmony Bioscien...
09/10/2024 12:50:56

UBS analyst Ashwani Verma initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Targ...

Needham Reiterates Buy on Harmony Bioscien...
08/08/2024 10:57:47

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

Analyst Expectations For Harmony Bioscienc...
08/06/2024 20:00:57

Needham Reiterates Buy on Harmony Bioscien...
08/06/2024 18:09:24

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

Harmony Biosciences Says On Track To Submi...
08/06/2024 11:58:15

Harmony Biosciences Reiterates 2024 Net Pr...
08/06/2024 11:57:31

As of June 30, 2024, Harmony had cash, cash equivalents and investments of $434.1 million, compared to $425.6 million as of Dec...

Harmony Biosciences Q2 2024 Adj. EPS $1.05...
08/06/2024 11:46:16

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $...

FDA Confirms Favorable Benefit-Risk Profil...
06/25/2024 12:07:04

Needham Reiterates Buy on Harmony Bioscien...
06/25/2024 09:30:27

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

Needham Reiterates Buy on Harmony Bioscien...
06/24/2024 17:01:55

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

Harmony Biosciences Announces FDA Approval...
06/24/2024 11:05:13

A Glimpse Into The Expert Outlook On Harmo...
06/21/2024 17:00:34

Citigroup Initiates Coverage On Harmony Bi...
06/21/2024 14:27:05

Citigroup analyst David Hoang initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price ...

Harmony Biosciences Reports Data For Pitol...
06/05/2024 12:26:09

Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excess...

Needham Maintains Buy on Harmony Bioscienc...
05/01/2024 09:34:56

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

harmony-biosciences-expands-it-cns-focused-pipeline-with-epilepsy-candidate-q1-earnings-beat-street-view

Harmony Biosciences Expands It CNS-Focused...
04/30/2024 15:44:54

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epil...

Key Takeaways From Harmony Biosciences Ana...
04/30/2024 13:00:33